Medication info
Diquban Tablet 160 mg (Valsartan)

Diquban Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Angkuk Pharmaceutical Co., Ltd.
Appearance
Oval film-coated tablet, orange with a grayish tint
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200807203 · Notified 2008.06.27 · Insurance code 650203020

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. If blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 20 ∼ 50 mL/min. When creatinine clearance is 10 ∼ 20 mL/min, initiate treatment with 40 mg of this medicine once daily. Do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients undergoing dialysis. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple concomitant therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose based on the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients undergoing dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this medicine daily. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age. Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Angkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used in the treatment of essential hypertension and is effective for the management of heart failure patients (NYHA class II to IV) who are intolerant to ACE inhibitors. It also helps reduce the risk of death in patients with left ventricular dysfunction or left ventricular systolic dysfunction after myocardial infarction. Therefore, it is used to improve hypertension, heart failure, and cardiac function decline after myocardial infarction.

How to take

Adult dose

Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. If blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 20 ∼ 50 mL/min. When creatinine clearance is 10 ∼ 20 mL/min, initiate treatment with 40 mg of this medicine once daily. Do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients undergoing dialysis. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple concomitant therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose based on the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients undergoing dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this medicine daily. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age. Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This drug can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with known allergies to this medication or its ingredients, women who are pregnant or breastfeeding, patients with severe liver or kidney disease, and those with a history of angioedema should not take this medication. Elderly patients, those with high potassium levels, liver disease, and cardiovascular disease should use this medication with caution, as they may experience hypotension or changes in kidney function, so their conditions should be monitored closely. During treatment with this medication, side effects such as dizziness, headache, fatigue, cough, and diarrhea may occur, and rarely severe allergic reactions or kidney dysfunction may develop, so consult a doctor immediately if symptoms arise. Blood pressure may drop suddenly or fainting may occur, so especially when starting treatment, it is important to begin with a low dose and monitor the condition closely. When taken together with other antihypertensive drugs, diuretics, or potassium-sparing medications, interactions may cause dangerously high potassium levels, so patients must inform their doctor of all medications they are taking. Women who are pregnant or planning a pregnancy should not take this medication, and its use is not recommended during breastfeeding. Use is not recommended for children or adolescents under 18 years of age, as safety and efficacy have not been established. In the case of overdose, blood pressure may drop too low, so seek appropriate medical treatment immediately.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also important to store it in a cool place below 30 degrees to maintain its efficacy.

Appearance and packaging

Appearance

Oval film-coated tablet, orange with a grayish tint

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.